StockIQ.techAsahi Kasei Corporation (3407.T) Stock Analysis
Free AI-powered analysis and research for Asahi Kasei Corporation stock
Sector: Industrials
3407.T snapshot
Data as of 2 Nov 2026 close. Updated daily.
Asahi Kasei Corporation scores 79/100 on StockIQ's model, which reads as strongly positive signals overall. The price is below its 200-day average and at 56% of its 52-week range, up 30.8% over the past year. Latest reported figures show a profit margin of 6.1%, return on equity of 9.8% and revenue growth of +11.9%.
What is driving the score
- RSI Neutral: +5
- Downtrend: -6
- MACD Bullish: +8
- Low P/E (11.3): +10
- Strong Liquidity (2.01 Current Ratio): +8
- Below MA200: -4
- Strong Momentum (+30.8% over 1 year): +8
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full 3407.T report
Asahi Kasei Corporation (3407.T) is listed in the Industrials sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze 3407.T Now →📰 Latest Update
Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults
Fri, October 9, 2026 at 10:41 PM UTC 4 min read
Asahi Kasei Therapeutics has received FDA approval for HOVILPRI® (pritelivir) tablets, designed to treat mucocutaneous HSV lesions in immunocompromised adults who are refractory to standard antiviral treatments. This approval is significant for investors as it expands the company's product portfolio and addresses a critical unmet medical need, potentially leading to increased revenue and market share in the antiviral segment. The successful launch of HOVILPRI® could enhance investor confidence in Asahi Kasei's growth prospects.